Global Science Marketing: Expanding Your Presence Across the Globe
With online communities and communication across labs increasing, science companies find themselves crossing national borders to establish an international presence. There are scie
A Bright Future for Pharma and Biotech in 2016
Before 2016 even officially kicked off, the life sciences industry received an early present to the tune of $32 billion. The House and Senate approved the 2016 spending bill, inclu
What You Cared About in 2015
As the year closes, one can’t help but reflect. So, we take a look back at our most popular blog posts from 2015. During the last 12 months, Chempetitive Group’s Chemunity blog
The Drug Development Process: A Rube Goldberg of Life Sciences?
A Rube Goldberg contraption is an over-engineered machine that uses chain reactions to accomplish the simplest of tasks in the most complicated of fashions, often in a comical way.
Massachusetts Paves the Way for Rare Disease and Orphan Drug Development
A recent article in the Boston Business Journal has revealed the full extent of the Bay State’s booming rare disease research sector. Massachusetts is home to more of the biggest
Animal Biotechnology Part Two: Advances in the Veterinary Space
As we learned in part one of this series, the field of animal biotechnology consists of two main arms of research. Our focus today is the veterinary side. Unlike the agricultural s
Rare Diseases: The Role of Social Media in Patient Recruitment
Since the passing of the Orphan Drug Act in 1983, the rate of drug development in the United States has seen a significant increase. The act directly impacted funding – a maj
When Pharma Trials Fail: A Case Study of Funky Cold Medina
Rapper Tone Loc could have been a part of a clinical research organization (CRO), yet he instead took to singing songs and providing cautionary tales of late-stage drug development
Want More Cures? Modernize Clinical Trials
As the federal government creates a plan to speed the pace of drug development in the U.S., one specialty contract research organization suggests that a more modernized approach to
2014 FDA Drug Approvals at 18-year High, but How Much New Ground Are We Breaking?
As the New Year bells chimed in 2015, the curtains drew shut on this century’s best year for novel-drug approvals. The U.S. FDA green-lighted 41 new agents for the U.S. market, i